Roots
Analysis
has done a detailed study on Targeted
Protein Degradation Market: Focus on Therapeutics and Technology Platforms
(based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags,
IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic
Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors),
2020-2030,
covering key aspects of the industry’s evolution and identifying potential
future growth opportunities.
To
order this 330+ page report, which features 130+ figures and 145+ tables,
please visit this link
Key Market Insights
§
§
§
§
§
§
§
§
§
§
For
more information please visit:
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE
SUMMARY
3.1. Context
and Background
3.2. Concept
of Protein Homeostasis
3.3. Discovery
of the Ubiquitin Proteasome System
3.3.1. Ubiquitin:
Structure and Function
3.3.2. Fundamentals
of the UPS
3.3.3. Components
of the UPS
3.4. Key
Steps Involved in the UPS
3.4.1. Ubiquitination:
The First Step
3.4.2. Proteasomal
Degradation: The Second Step
3.5. Therapeutic
Applications of the UPS
3.6. Advantages
and Challenges Associated with Ubiquitin Enzyme Inhibitors
3.7. Targeted Protein Degradation: Enhancing
Ubiquitination to Degrade Undruggable Targets
3.7.1. Brief
History of Targeted Protein Degradation
3.8. Types
of Protein Degraders
3.8.1. Selective
Hormone Receptor Degraders (SHRDs)
3.8.2. Immumodulatory
Imide Drugs (IMiDs)
3.8.3. PROTACs
3.8.4. Other
Chimeras (ENDTACs, LYTACs and PHOTACs)
3.8.4.1. Endosome Targeting Chimeras
(ENDTACs)
3.8.4.2. Lysozyme targeting chimeras (LYTACs)
3.8.5. Specific and Nongenetic Inhibitor-of-Apoptosis
Proteins (IAP)-dependent Protein Erasers (SNIPERS)
3.8.6. Hydrophobic
Tag
3.8.7. Molecular
Glues
3.8.8. DUB
Inhibitors
3.9. Growth
Drivers and Roadblocks
4. CURRENT
MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics and
Technologies: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Type of Target Enzyme
4.2.6. Analysis by Type of Target Protein
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeutics and
Technologies: List of Research Tools / Key Technology Platforms
4.4. Targeted Protein Degradation-based Therapeutics and
Technologies: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Location of Headquarters
4.4.3. Analysis by Size of Company
4.4.4. Analysis by Type of Protein Degrader
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Clinical Candidates
5.2.1. Radius Health
5.2.1.1. Company Overview
5.2.1.2. Targeted Protein Degradation-based
Drug Portfolio
5.2.1.2.1. Product
Description: Elacestrant
5.2.1.3. Recent Developments and Future
Outlook
5.2.2. Celgene
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Targeted Protein Degradation-based
Drug Portfolio
5.2.2.3.1. Avadomide
(CC-122)
5.2.2.3.2. Iberdomide
(CC-220)
5.2.2.4. Recent Developments and Future
Outlook
5.2.3. Sanofi Genzyme
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Targeted Protein Degradation-based
Drug Portfolio
5.2.3.3.1. Product
Description: SAR439859
5.2.3.4. Recent Developments and Future Outlook
5.3. Developers with Preclinical /
Early-stage Clinical Candidates
5.3.1. Arvinas
5.3.2. Captor Therapeutics
5.3.3. Genentech
5.3.4. Kymera Therapeutics
5.3.5. Mission Therapeutics
5.3.6. Progenra
5.3.7. Zenopharm
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Targeted Protein Degradation-based Therapeutics and
Technologies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of
Clinical Trials
6.3.3. Geographical Analysis by Enrolled
Patient Population
6.3.4. Analysis by Type of Protein Degrader
6.3.5. Analysis by Phase of Development
6.3.6. Analysis by Study Design
6.3.7. Analysis by Type of Sponsor /
Collaborator
6.3.8. Most Active Players: Analysis by
Number of Registered Trials
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Therapeutic Area
6.3.11. Analysis by Clinical Endpoints
7. KOL ANALYSIS
7.1. Chapter
Overview
7.2. Scope
and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and
Technologies: List of Principal Investigators Involved in Clinical Trials
7.3.1. Analysis
by Type of Organization
7.3.2. Analysis
by Designation
7.3.3. Geographical
Distribution
7.3.4. Analysis
by Therapeutic Focus
7.3.5. Analysis
by Phase of Development and Type of Degrader
7.4. Prominent
Key Opinion Leaders
7.5. KOL Benchmarking: Roots Analysis
versus Third Party Scoring (ResearchGate Score)
7.6. Most
Active Key Opinion Leaders
7.6.1. KOL
Profile (Hagop Youssoufian)
7.6.2. KOL
Profile (Patricia LoRusso)
7.6.3. KOL
Profile (Johann De Bono)
7.6.4. KOL
Profile (John N Nemunaitis)
7.6.5. KOL
Profile (Robert Morgan)
7.6.6. KOL
Profile (Edward O’Mara)
8. PUBLICATION
ANALYSIS
8.1. Chapter
Overview
8.2. Scope
and Methodology
8.3. Targeted Protein Degradation-Based Therapeutics and
Technologies: Recent Publications
8.3.1. Analysis
by Year of Publication
8.3.2. Analysis
by Study Objective
8.3.3. Emerging
Focus Areas
8.3.4. Analysis
by Type of Protein Degrader
8.3.5. Analysis
by Target Protein
8.3.6. Analysis
by Target Enzyme
8.3.7. Analysis
by Target Indication
8.3.8. Analysis
by Type of Publisher
8.3.9. Leading
Players: Analysis by Number of Publications
8.3.10. Leading
Players: Geographical Analysis by Number of Publications
8.3.11. Key
Journals: Analysis by Number of Publications
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Targeted Protein Degradation:
Funding and Investment Analysis
9.3.1. Analysis by Number of Funding
Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount
Invested across Different Protein Degraders
9.3.5. Analysis by Number of Funding Instances and Amount
Invested across Different Therapeutic Areas
9.3.6. Analysis by Amount Invested across Different Protein
Degradation Technology Platforms
9.3.7. Most Active Players: Analysis by
Number of Funding Instances
9.3.8. Most Active Investors: Analysis by
Number of Funding Instances
9.3.9. Geographical Analysis by Amount
Invested
9.4. Concluding Remarks
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Targeted Protein Degradation-based Therapeutics and
Technologies: Recent Collaborations and Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Protein Degrader
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Different Protein
Degradation Technology
10.3.6. Most Active Players: Analysis by
Number of Partnerships
10.3.7. Geographical Analysis
10.3.7.1. Most
Active Players: Regional Analysis by Number of Partnerships
10.3.7.2. Intercontinental
and Intracontinental Agreements
11. MARKET SIZING AND OPPORTUNITY
ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Forecast
Methodology
11.3. Overall Targeted Protein Degradation-based
Therapeutics and Technologies Market, 2020-2030
11.3.1. Targeted Protein Degradation-based Therapeutics and
Technologies Market by Upfront Payments, 2020-2030
11.3.2. Targeted Protein Degradation-based Therapeutics and
Technologies Market by Milestone Payments, 2020-2030
11.3.3. Targeted Protein Degradation-based Therapeutics and
Technologies Market: Distribution by Type of Protein Degrader
11.3.3.1. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Degronimids, 2020-2030
11.3.3.2. Targeted Protein Degradation-based Therapeutics and
Technologies Market for PROTACs, 2020-2030
11.3.3.3. Targeted Protein Degradation-based Therapeutics and
Technologies Market for SARDs / SERDs, 2020-2030
11.3.3.4. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Specific BET and DUB Inhibitors, 2020-2030
11.3.3.5. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Other Protein Degraders, 2020-2030
11.3.4. Targeted Protein Degradation-based Therapeutics and
Technologies Market: Distribution by Therapeutic Area
11.3.4.1. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Neurodegenerative Disorders, 2020-2030
11.3.4.2. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Oncological Disorders, 2020-2030
11.3.4.3. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Other Therapeutic Areas, 2020-2030
11.3.5. Targeted Protein Degradation-based Therapeutics and
Technologies Market: Distribution by Route of Administration
11.3.5.1. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Oral Route, 2020-2030
11.3.5.2. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Intravenous Route, 2020-2030
11.3.5.3. Targeted Protein Degradation-based Therapeutics and
Technologies Market for Other Routes, 2020-2030
11.3.6. Targeted Protein Degradation-based Therapeutics and
Technologies Market: Distribution by Geography
11.3.6.1. Targeted Protein Degradation-based Therapeutics and
Technologies Market in North America, 2020-2030
11.3.6.2. Targeted Protein Degradation-based Therapeutics and
Technologies Market in Europe, 2020-2030
11.3.6.3. Targeted Protein Degradation-based Therapeutics and
Technologies Market in Asia-Pacific, 2020-2030
13. CONCLUDING REMARKS
13.1. Chapter
Overview
13.2. Key
Takeaways
14. APPENDIX
1: TABULATED DATA
15. APPENDIX
2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415